| Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. | |
| | |
MedLine Citation:
|
PMID: 17163277 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: The aim of this study was to estimate the cost-effectiveness of schizophrenia relapse prevention in Spain using data from the ZEUS (Ziprasidone-Extended-Use-in-Schizophrenia) study. METHODS: Treatment of schizophrenia was modeled over 1 year using a retrospective deterministic model from the Spanish National Health System (NHS) perspective (year 2005). The primary outcome was the probability of relapse occurring within a 52-week period of treatment with daily doses of ziprasidone 40-160mg versus placebo. Data were obtained from a randomised, double-blind clinical trial (n = 218 patients). Antipsychotic cost, concomitant medications to treat adverse events (for example extrapyramidal symptoms) and medical costs associated with adverse events were derived from the clinical trial results and a Spanish health cost database. The average cost of a relapse admitted to hospital in Spain (3421 euro) was obtained from a retrospective study. RESULTS: The probability of psychosis relapse was 0.77 with placebo, and 0.43, 0.35, 0.36 and 0.38 with ziprasidone daily doses of 40, 80, 160mg and average dose, respectively (p < 0.01 vs placebo in all cases). The average annual incremental cost per relapse avoided was 186 euro for the average dose, ranging from a saving of 557 euro (80 mg/day) to an incremental cost of 1015 euro (160 mg/day), and was lower in all cases than the minimum cost of a relapse (2830 euro). CONCLUSIONS: According to this evaluation, psychosis relapse prevention with ziprasidone is cost effective compared with no treatment from the Spanish NHS perspective. Ziprasidone therapy avoids a considerable number of relapses at a reasonable cost, producing cost savings. |
| | |
Authors:
|
Miguel Bernardo; Jose Ramón Azanza; Carlos Rubio-Terrés; Javier Rejas |
Related Documents
:
|
2127007 - Primary prevention of coronary heart disease in the federal republic of germany. analys... 11271867 - Chronic fatigue in general practice: economic evaluation of counselling versus cognitiv... 18360607 - Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cel... 9916907 - Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who develo... 1678937 - Psychotic depression: a review and clinical experience. 18297597 - Cognitive and functional outcomes of terror victims who suffered from traumatic brain i... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical drug investigation Volume: 26 ISSN: 1173-2563 ISO Abbreviation: Clin Drug Investig Publication Date: 2006 |
Date Detail:
|
Created Date: 2006-12-13 Completed Date: 2007-02-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9504817 Medline TA: Clin Drug Investig Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 447-57 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, Hospital Clinic i Provincial, Barcelona, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antipsychotic Agents / administration & dosage, economics, therapeutic use Chronic Disease Cost-Benefit Analysis / methods Dose-Response Relationship, Drug Drug Administration Schedule Humans Models, Econometric Piperazines / administration & dosage, economics, therapeutic use* Program Evaluation / methods Recurrence Reproducibility of Results Schizophrenia / economics, prevention & control* Spain Thiazoles / administration & dosage, economics, therapeutic use* Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Antipsychotic Agents; 0/Piperazines; 0/Thiazoles; 146939-27-7/ziprasidone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Relationship between the frequency of blood pressure self-measurement and blood pressure reduction w...
Next Document: Serum levels and possible haemodynamic effects following anorectal application of an ointment contai...